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Summary Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA acts in vivo by
binding to a membrane receptor known as uPAR. In this study, uPA and uPAR levels were semiquantitated by immunocytochemistry in 36
primary breast carcinomas. Using monoclonal antibody HD-UK 1, uPA was detected both in stromal and in malignant cells. However, the
predominant location was in the stromal cells. Using double-staining, cells containing uPA were also found to coexpress eithercytokeratin (an
epithelial cell marker) or more frequently KP1 (a macrophage/monocyte cell marker). With monoclonal antibody HD-uPAR 13.1, uPAR was
localized principally to spindle- or macrophage-like stromal cells, especially when these cells surrounded invasive breast cancer. In contrast,
uPAR was only rarely detected in cancer cells and was not detected in normal epithelia surrounding tumour or in areas of adenosis. uPA
levels in both stromal and epithelial cells were significantly correlated with those for uPAR. We conclude that both uPA and its receptor are
mostly present in stromal cells in invasive breast carcinomas. These results suggest that stromal cells collaborate with malignant cells to
mediate metastasis.
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The prognosis of breast and other cancers is ultimately determined
by the ability of a tumour to invade and metastasize. During the
process of cancer invasion and metastasis, natural barriers, such
as the interstitial matrix and basement membranes, have to be
degraded. Degradation of these barriers is mediated by specific
proteolytic enzymes released from the primary cancers (for
reviews, see Duffy, 1992 and Andreasen et al, 1997). One of the
key proteases involved in the degradation of the extracellular
matrix (ECM) is urokinase plasminogen activator (uPA). uPA is a
serine protease implicated in multiple activities, such as proteo-
lysis, cellular proliferation, migration and adhesion (reviewed in
Duffy, 1993; Dan0 et al, 1994). As a protease, uPA catalyses the
conversion ofinactive plasminogen to plasmin. Plasmin is a broad-
spectrum protease that catalyses the degradation ofmost substrates
in the ECM. In addition to activating plasminogen, uPA can also
activate certain growth factors, such as latent hepatocyte growth
factor (HGF) (Mars et al, 1993). HGF is a growth stimulator not
only for hepatocytes but also for various types of epithelial and
endothelial cells (Boros et al, 1995). In vivo, uPA appears to act by
binding to a membrane receptor termed uPAR (Duffy, 1993; Dan0
et al, 1994). Binding ofuPA to its receptor is specific, saturable and
appears to lead to signal transduction (Dan0 et al, 1994). The aim
ofthis investigation was to semiquantitate levels ofuPA and uPAR
in invasive breast cancers using immunocytochemistry.
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MATERIALS AND METHODS
Breast tumour tissue was obtained at the time of resection and
snap frozen in optimal cutting temperature compound (OCT).
Five-micron cryostat sections were cut, dried overnight at room
temperature, fixed in acetone for 10 min at room temperature and
stored at -70°C until use. Sections were allowed to thaw for 2 h at
room temperature before immunohistochemical staining.
Thirty-six samples of invasive breast cancers were stained for
uPA with monoclonal antibody HD-UK1 and for uPAR with
monoclonal antibody HD-uPAR 13.1 (Schaefer et al, 1994). Both
of these antibodies were used at a concentration of 2 gg ml-'.
Incubations were carried out at room temperature for 2 h.
Endogenous peroxidase activity was blocked using 0.03%
hydrogen peroxide. A standard avidin-biotin (ABC) technique
was employed using a Vectastain Elite Murine ABC kit (Vector
Laboratories, Burlingame, CA, USA) to demonstrate the antigens.
All incubations were carried out as per kit instructions. 3'3'-
Diaminobenzidine tetrachloride (DAB) was used as the chro-
mogen. All steps were performed in a moist chamber. The sections
were counterstained using Harris' haematoxylin, dehydrated,
cleared and mounted in DPX (BDH).
In order to check staining specificity, the following controls
were included:
(a) Positive controls consisting ofnormal kidney and breast carci-
noma known to be positive for both uPA and uPAR by ELISA
(Duggan et al, 1995).
(b) Negative controls involved omission ofthe primary antibody
and its replacement by serum or the use of an isotype control.
(c) Sections from four ofthe above carcinomas were stained with
additional antibodies against uPA and uPAR. For uPA, these
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Figure 1 Immunocytochemical staining of uPA and uPAR in breast carcinoma. (A) uPA, (B) uPAR, (C) double-staining of uPA and macrophage-specific
marker KP1 and (D) double-staining of uPA and CAM 5.2. Scale bar for A and D = 15 ,um, for B and C = 30 gm. Arrow in C indicates a cell positive for both uPA
and KP1, while the arrow in D shows a cell positive for both uPA and CAM 5.2
antibodies were derived from hybridoma clones 5, 6, 12 and
16 provided by the Finsen Laboratory, Copenhagen, and MAb
no. 3689 obtained from American Diagnostica, 222 Railroad
Ave., Greenwich, CT, USA. All ofthese antibodies were used
at a concentration of 5 gg ml'. For uPAR, the R2 antibody
(Finsen Laboratories) was used at a dilution of 5 gg ml'.
(d) In addition to the use offrozen material, staining was carried
out on sections from four cases ofparaffin-embedded and
formalin-fixed tissue. Before immunostaining the fixed tissue,
digestion with pronase was carried out at 37°C for 20 min.
In an attempt to better characterize those cells showing
reactivity for uPA and uPAR at the tumour-stromal interface, we
performed double-staining on paraffin-embedded and formalin-
fixed tissue with the following antibodies: CAM 5.2 (Becton-
Dickinson), a marker for epithelial cytokeratin, and CD68 (KP1,
Dako), a marker for histiocytes. The KPl antibody was used at a
dilution of 1:80 and the CAM 5.2 was used neat. Incubations were
carried out at room temperature for 2 h. Antigens were visualized
using the Vectastain alkaline phosphatase substrate kit I (Vector
Red, Vector Laboratories). All steps were performed in a moist
chamber. The sections were then lightly counterstained with
Mayer's haematoxylin, dehydrated and mounted in DPX.
The immunohistochemical staining of uPA and uPAR was
evaluated semiquantitatively using a four-point scoring system.
Immunoreactivity of tumour cells and stromal cells were sepa-
rately evaluated as follows: level 0, no staining; level 1, 1-10% of
cells positive; level 2, 11-49% ofcells positive; level 3, over 50%
of cells positive. A minimum of 200 tumour cells and 50 stromal
cells were counted.
RESULTS
Immunostaining for uPA
Using antibody HD-UK1, immunoreactivity for uPA was seen in the
proximal tubules ofthe controlkidney sections as expected. Inbreast
carcinomas, immunoreactivity for uPA was seen predominantly in
stromal cells, particularly those located at the tumour-stromal inter-
face (see Figure 1A). The stromal cells showing immunoreactivity
were elongated slender spindle cells recognized by conventional
haematoxylin and eosin (H & E) staining as stromal fibroblasts,
myofibroblasts andmacrophage-like cells. Lymphocytes andplasma
cells were not immunoreactive. Normal ducts and lobules were not
immunoreactive, nor were blood vessels or nerves. The proportion
of malignant and stromal cell staining for uPA is shown in Table 1.
While detectable stromal cell staining (i.e. score 1 or greater) was
found in 34 out of 36 (94.4%) cases, malignant cell staining was
found in only 23 out of36 (63.6%) samples. Similarly, high stromal
cell staining (i.e. level 3 staining) was found in 15 (41.7%) compared
with only six (16.7%) cases with high levels of epithelial staining.
Staining with the other uPA antibodies (i.e. clones 5, 6, 12, 16 and
MAb no. 3689) was similar to HD-UK1. In addition, similar staining
for HD-UKl was found in frozen and fixed tissue.
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Table 1 The proportion of malignant and stromal cell staining for uPA
uPA staining Tumour cells Stromal cells
score n(%) n(%)
3 6 (16.67) 15 (41.66)
2 6 (16.67) 6 (16.67)
1 11 (30.56) 14 (38.88)
0 13 (36.10) 1 (2.78)
Table 2 The proportion of malignant and stromal cell staining for uPAR
uPAR staining Tumour cells Stromal cells
score n (%) n(%)
3 4 (11.11) 18 (50.00)
2 5 (13.88) 7 (19.44)
1 8 (22.23) 10 (27.78)
0 19 (52.78) 1 (2.78)
Using double-labelling techniques, cells expressing uPA were
shown to coexpress eithercytokeratin (an epithelial marker; Figure
ID) or more commonly KPl (a macrophage/monocyte marker;
Figure IC). These results support the finding by conventional
haematoxylin and eosin staining that both macrophages or faculta-
tive fibroblasts express uPA as well as tumour cells.
Immunostaining for uPAR
Using sections of normal kidney, uPAR staining with antibody
HD-uPAR 13.1 was present in tubular epithelial cells, in occa-
sional glomerular mesengial cells and in some inflammatory cells
in the interstitial tissue. In addition, staining was seen in tubule
luminal precipitates. In breast tumours, uPAR immunoreactivity
was located almost exclusively in spindle-like- ormacrophage-like
cells, particularly surrounding invasive breast cancer (Figure 1B).
Staining was rarely present in the carcinoma cells, apart from
expression by rare single cells. uPAR was also present within the
necrotic debris in intraduct carcinoma, within foamy cells (most
likely to macrophage origin) and within intraduct carcinoma. In
tumours that had a large number of infiltrating lymphocytes, the
lymphocytes were negative. uPAR was not present within the
normal epithelium surrounding the breast tumour or within areas
of adenosis. Staining of lymphovascular spaces and polymorpho-
nuclear leucocytes was also seen. A similar pattern ofstaining was
seen with monoclonal antibody R2. In addition, frozen and
paraffin-embedded formalin-fixed tissue gave equivalent staining
with the HD-uPAR 13.1 antibody.
The staining scores for uPAR in epithelial and stromal cells are
summarized in Table 2. Positive staining (i.e. greater than level 1)
in malignant cells was found in 17 out of 36 (47.2%) specimens,
while stromal staining was present in 35 out of 36 (97.2%). High
levels of uPAR staining (i.e. level 3) was detected in carcinoma
cells in four cases (11.1%) and in stromal cells in 18 (50%)
tumours. Using double-labelling techniques, cells expressing
uPAR were also commonly immunoreactive for the monocyte/
macrophage marker KPI. Convincing positivity in cells staining
for the epithelial marker cytokeratin was also observed (data
not shown).
Relationship between uPA and uPAR staining
uPA staining scores correlated significantly with those for uPAR in
both malignant cells (r= 0.694, P= 0.0001) and stromal cells
(r = 0.582, P = 0.0007). Similarly, the combination oftumour and
stromal cell staining resulted in a significant relationship between
uPA and uPAR (r = 0.562, P = 0.0013). In contrast, there was no
significant relationship between uPA levels in stromal and
malignant cells. uPAR levels in stromal and epithelial cells also
showed no significant correlation.
Relationship between uPA and uPAR staining and
established prognostic markers
No significant relationship was found between uPA staining levels
and either tumour size, nodal status or oestrogen receptor status.
Similarly, uPAR levels did not correlate with these established
prognostic markers in breast cancer.
DISCUSSION
This is one of the first reports to both semiquantitate uPA staining
and localize the cell type containing the protease using double-
staining. Using a number of monoclonal antibodies, we demon-
strated that the uPA protein in breast carcinoma was present in
both malignant and stromal cells. However, uPA immunoreactivity
was localized predominantly to stromal cells. This staining pattern
was seen using both frozen and paraffin-embedded formalin-fixed
tissue. Recently, Christensen et al (1996) also reported that uPA
immunoreactivity was present in different cell types in breast
carcinoma. In this study, staining was reported to be intense in
macrophages and mast cells, and moderate in epithelial cells,
fibroblasts and endothelial cells. Other studies, however, have
reported that uPA is present predominantly in epithelial cells in
breast cancer. Del Vecchio et al (1993) found that uPA staining
was most pronounced in malignant cells with only a faint reaction
in fibroblast-like cells. Similarly, Jankun et al (1993) detected uPA
mostly in malignant cells, but also found the protease to be present
in some scattered macrophages.
The reasons for these conflicting results on the cellular localiza-
tion of uPA in breast cancer are unknown. Possible factors that
might be expected to contribute to the variable results could be
different methods of storing and processing tissue (e.g. fresh vs
formalin-fixed and paraffin-embedded tissue) and the use of anti-
bodies ofdifferent specificities. In this investigation, however, we
obtained a similar pattern of staining using six different antibodies
against uPA. Furthermore, similar staining was seen in fresh and
paraffin-embedded tissue with the antibody HD-UKI.
While most studies using immunocytochemistry show uPA to
be present in both stromal and epithelial cells in breast cancer,
Nielsen et al (1996) using in situ hybridization, demonstrated that
uPA mRNA was present almost exclusively in stromal cells, i.e. in
myofibroblasts adjacent to cancer cells. However, Escot et al
(1996) detected uPA mRNA in both stromal and malignant cells in
breast cancer. Again, these conflicting results may be related to the
preparation and storage oftissue. In addition, the sensitivity of the
probes used may have contributed to these discordant findings.
Compared with uPA, less work has been carried out on
immunostaining for uPAR in breast cancer. In this investigation,
we show that the predominant location ofuPAR immunoreactivity
was in the macrophage-like cells surrounding invasive malignant
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cells. However, some malignant cells also stained positive for
uPAR. Similar findings have been reported by other investigators
(Pyke et al, 1993; Bianchi et al, 1994; Christensen et al, 1996).
Carriero et al (1994) found that breast epithelial cells were unreac-
tive to uPAR antibodies unless pretreated with an acid wash. These
findings suggest that binding ofuPAR to its ligand may prevent its
recognition by certain anti-uPAR antibodies, as acid pretreatment
is thought to cause dissociation of uPA from its receptor. Few
studies appear to have been carried out on the localization ofuPAR
mRNA in breast cancer. In colorectal cancer, however, mRNA for
uPAR has been detected in both cancer and stromal cells (Pyke et
al, 1991), whereas, in malignant melanomas, uPAR was localized
exclusively to tumour cells (de Vries et al, 1994).
The significant correlation between uPA and uPAR levels
reported here is in agreement with previous reports using ELISA
(Duggan et al, 1995; Gr0ndahl-Hansen et al, 1995). These findings
suggest that the expression ofboth the ligand and its receptor may
be regulated by the same factors. Evidence for this co-ordinated
regulation of uPA and uPAR was recently obtained using cultured
keratinocytes (Bechtel et al, 1996). Using these cells, levels of
both uPA and its receptor were induced by interleukin- 13 and
tumour necrosis factor-a.
In this study, we found no significant relationship between uPA
and uPAR levels and established prognostic markers, such as
tumour size, nodal status or ER status. Similar findings have also
been reported using ELISA to measure uPA and uPAR (Janicke et
al, 1992; Duggan et al, 1995). Despite these findings, high levels of
either uPA or uPAR as determined by ELISA are associated with
poor patient outcome in breast and other malignancies (for review,
see Duffy et al, 1996). uPA, in particular, is a strong and indepen-
dent prognostic marker in breast cancer. Furthermore, in multiple
studies, uPA has been shown to correlate with patient outcome in
axillary node-negative breast cancer patients (Duffy et al, 1996).
In conclusion, the localization ofboth uPA and uPAR to stromal
cells suggests that these cells, in concert with malignant cells, may
mediate cancer invasion and metastasis. Stromal cells are thus a
new potential target for antimetastatic therapies.
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